Sugar Research Foundation Project 226 funded the 1967 McGandy–Hegsted–Stare *NEJM* literature review that elevated fat and downplayed sucrose while omitting SRF’s role. Kearns, Schmidt, and Glantz’s 2016 *JAMA Internal Medicine* analysis of university-archive industry documents reconstructs that playbook; a 2015 *PLOS Medicine* sibling shows agenda-setting on federal caries research.
In the mid-1960s the Sugar Research Foundation paid for a literature review on diet and coronary heart disease. In 1967 that review appeared in the New England Journal of Medicine as a two-part article by McGandy, Hegsted, and Stare. It told readers there was “no doubt” that the dietary intervention required to prevent CHD was to cut cholesterol and swap polyunsaturated fat for saturated fat. Sucrose hazards were minimized. The review disclosed other funding streams for the authors’ experimental work. It did not disclose that the Sugar Research Foundation had sponsored the review, set its objective, contributed articles, and received drafts. That gap sat in university archives until a 2016 historical analysis put the correspondence on the public map.
JAMA Internal Medicine
Project 226
Early warning papers in the 1950s and 1960s had already opened a fight between fat-centered and sucrose-centered CHD hypotheses. Industry documents reconstructed by Cristin Kearns, Laura Schmidt, and Stanton Glantz show the SRF treating that fight as a business risk. A low-fat American diet, trade-group materials had noted years earlier, could raise per-capita sucrose consumption. Project 226—the foundation’s first CHD research project—was not a random grant. It was a literature review aimed at the comparative case for fat versus sugar, overseen through Harvard nutrition channels including D. Mark Hegsted.
The scientific common sense that filtered into mid-century dietary advice elevated blood cholesterol and saturated fat. That posture had real epidemiologic and clinical roots; this page does not erase them. The archival point is narrower and sharper. When an industry trade group funds the review that helps lock fat-first language into a premier journal—and hides its own hand—the “official” nutrition story acquires a commercial editor. Policymakers and clinicians reading NEJM in 1967 could not see that editor on the page.
UCSF’s announcement of the document find states the mechanism in plain institutional prose: industry money, draft review, undisclosed role, narrative tilt toward fat and away from sucrose as co-villain.
The 2016 analysis draws on hundreds of pages from the University of Illinois Archives (Roger Adams, SRF scientific advisory board) and the Harvard Medical Library (Hegsted correspondence), totaling well over a thousand pages across the wider sugar-paper set the authors describe. Chronology in those letters shows SRF executives selecting the review’s objective, sending materials for inclusion, and commenting on drafts before publication. Project 226’s product is the 1967 NEJM review. The finding is historical and documentary: sponsorship and participation existed; disclosure did not.
That is different from proving, in 2016 paper form, every modern claim about added sugars and heart disease. Mixing those layers is how online diet wars go wrong. The Archive keeps them separate. Archival guilt is about process and nondisclosure. Clinical dose-response is a later evidence shelf.
Why the Story Stayed Quiet
Personal papers and trade-association files are not press releases. As long as the correspondence lived in boxes, the NEJM review could be cited as independent elite consensus. Historical analysis only became possible when researchers matched published text to sponsored objectives in the archives. UCSF’s Industry Documents Library later institutionalized food-industry document collecting in the same family of methods that built tobacco archives—another reason the sugar papers matter beyond one journal fight.
A 2015 PLOS Medicine paper by Kearns and colleagues applies the same internal-document method to sugar-industry influence on the National Institute of Dental Research’s 1971 National Caries Program. Unable to deny sucrose’s role in tooth decay, the industry steered federal priorities toward interventions that left consumption less threatened—seventy-eight percent of an industry submission, the authors report, entered NIDR’s call for applications. When science cannot be wished away, agenda-setting becomes the playbook.
Disclosure rules in mid-century journals were thinner than today’s norms, but the letters still show why silence mattered. A 1967 NEJM reader met a polished argument that treated sucrose evidence harshly and fat evidence generously. Without an SRF sponsor line, that asymmetry looked independent; with Adams and Hegsted files restored, it looks like product. Kearns and colleagues reconstruct a funding-and-editing episode and urge committees to weigh industry-funded studies differently—they do not pretend a historical article replaces contemporary trials.
The playbook’s durability is the second so-what. Fat-first advice had scientific supporters outside the SRF payroll. Industry did not need to invent the cholesterol hypothesis. It needed to subsidize the review that made sidelining sucrose look like settled hierarchy rather than contested comparison—cheaper than winning every lab argument, and harder to see in real time.
Date discipline keeps the page honest. Project 226 sits in 1965–66; the NEJM parts run in 1967; the sugar papers land in September 2016. Between those poles stretch decades of guidelines and later free-sugar warnings. Continuity of commercial incentive is not identical to continuity of every scientific claim. The documents settle a 1960s influence operation on CHD narrative; they leave today’s dose-response fights to today’s evidence.
Myth Discipline
Refuse the slogan that sugar was never a CHD research question. Refuse the slogan that fat was a manufactured villain with no biology behind it. Refuse treating the 2016 historical paper as if it were a randomized trial of today’s soft drinks. What the packets settle is narrower and harder to shrug off: a trade foundation paid for a CHD literature review, shaped it, and kept that role off the published page while fat-first advice hardened into common sense.
What the Paper Trail Settles
Settled on the documents: SRF Project 226; McGandy–Hegsted–Stare NEJM 1967 review; undisclosed SRF sponsorship and participation; Adams/Hegsted archival correspondence as reconstructed in JAMA Internal Medicine 2016; parallel industry-document findings on the NIDR caries program. Overclaim to refuse: that this single episode explains all later nutrition policy, or that exposing it erases saturated-fat evidence. Officials and journals once presented a fat-first CHD story as settled diet science. The sugar papers show who helped edit the footnotes—read with the JAMA article and the university archive doors open.
